In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Life Sciences 4.0: Securing value through data-driven platforms

When the human body is the biggest data platform, who will capture value?

Life sciences companies have already started to respond to this new demand-driven environment by shifting their business models away from blockbuster and specialty products and toward outcomes-based business models. They must now consider how and when to participate in emerging care platforms that seamlessly collect, combine and share a variety of health data in real-time. This will involve the formation of agile, and often short-term, partnerships and collaborations. We call the data-centric, platform-based business models that emerge from such efforts Life Sciences 4.0.

Embracing Life Sciences 4.0 is both an urgent need and an opportunity. If life sciences companies can leverage platforms to combine their proprietary data with environmental, behavioral and financial insights, they can position themselves to capture maximum future value in the market.

Embracing Life Sciences 4.0 is both an urgent need and a blossoming opportunity that has yet to be realized. If life sciences companies can leverage platforms to combine their proprietary data with environmental, behavioral and financial insights, they can position themselves to capture maximum future value in the market.

Pamela Spence, EY Global Life Sciences Industry Leader

In the retail and transportation industries, where data exchange is fast and easy, companies have eliminated long-standing inefficiencies and created benefits for themselves and their customers. Life Sciences 4.0, likewise, can help medtechs and biopharmas unlock and capture value, allowing companies to co-create new solutions that drive improved health outcomes and preserve, or even improve, their position in a rapidly changing health ecosystem.

To seize the upside of disruption in this transformative age, executives should ask themselves the following questions:

  • How will your organization transform its business model to create shared value focused on personalized outcomes and fueled by unlocking the power of data?
  • How will your organization build new capabilities organically, by acquisition or by flexible partnerships?
  • How will your organization ultimately secure value through platform-based businesses?

Click here to keep reading and download the complete report.

Advertisement

Topics

Key Documents

Advertisement
UsernamePublicRestriction

Register

IV005351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel